Please use this identifier to cite or link to this item:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson’s disease patients

AuthorsSantos-García, Diego; Deus Fonticoba, T. de; Suárez-Castro. Ester; Aneiros Díaz, A.; Paz González, J. M.; Feal Panceiras, M. J.; García-Sancho, Carlos; Jesús Maestre, Silvia; Mir, Pablo CSIC ORCID; Aguilar, M.; Pastor, P.; Hernández-Vara, J.; Fábregues-Boixar, O. de; Puente, V.; Crespo Cuevas, A.; González-Aramburu, Isabel; Infante, Jon; Carrillo, Fátima; Pueyo Morlans, M.; Escalante, Sonia; Bernardo Lambrich, N.; Solano Vila, B.; Cots Foraster, A.; Martínez Martín, Pablo
KeywordsC-reactive protein
Parkinson’s disease
Issue Date31-Oct-2019
PublisherSpringer Nature
CitationJournal of Neural Transmission 126: 1599-1608 (2019)
AbstractC-reactive protein (CRP) is a biomarker of systemic inflammation that has been linked to accelerated decline in walking speed in older adults. The aim of the present study was to compare the CRP levels of PD patients with vs patients without freezing of gait (FOG). Patients and controls participating in the COPPADIS-2015 study that performed blood extraction for determining molecular serum biomarkers were included. Patients with FOG were identified as those with a score of 1 or greater on item-3 of the Freezing of Gait Questionnaire (FOG-Q). Immunoassay was used for determining ultrasensitive CRP (US-CRP) level (mg/dL). In the PD group (n = 225; 61.8 ± 9.5 years old, 61.8% males), 32% of the patients presented FOG but none in the control group (n = 65; 60.3 ± 6.1 years old, 56.9% males) (p < 0.0001). Differences in US-CRP level were significant in patients with FOG vs patients without FOG and vs controls (0.31 ± 0.52 vs 0.16 ± 0.21 vs 0.21 ± 0.22; p = 0.04). Significant differences were also observed between patients with vs without FOG (p = 0.001) but not between patients and controls (p = 0.163). US-CRP level was related to FOG (OR = 4.369; 95% CI 1.105–17.275; p = 0.036) along with H&Y (OR = 2.974; 95% CI 1.113–7.943; p = 0.030) and non-motor symptoms burden (NMSS total score; OR = 1.017; 95% CI 1.005–1.029; p = 0.006) after adjusting for age, gender, disease duration, equivalent daily levodopa dose, number of non-antiparkinsonian drugs per day, motor fluctuations, cognition, motor phenotype, and chronic use of anti-inflammatory drugs. The present study suggests that serum US-CRP level is related to FOG in PD patients. Inflammation could be linked to FOG development.
DescriptionCOPPADIS Study Group.
Publisher version (URL)
Identifiersdoi: 10.1007/s00702-019-02096-8
e-issn: 1435-1463
issn: 0300-9564
Appears in Collections:(IBIS) Artículos

Files in This Item:
File Description SizeFormat
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Google ScholarTM




WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.